BioCentury
ARTICLE | Company News

Gilead grows fibrosis pipeline with Scholar Rock deal

December 21, 2018 7:24 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) acquired options to license transforming growth factor β 1 (TGFβ1) programs from Scholar Rock Holding Corp. (NASDAQ:SRRK) as the bellwether looks to expand its fibrotic pipeline.

Gilead received options to two TGFβ1 inhibitor programs and one undisclosed TGFβ discovery program for fibrosis indications for $80 million up front, including $50 million in cash and a $30 million equity investment, and up to $1.5 billion in milestone payments, plus high single-digit to low double-digit tiered royalties...